With decades of experience across clinical planning, patient identification, and recruitment strategy, Citeline brings together data, Al, and human expertise to help sponsors find the right patients — sooner. This session covers the practical strategies and end-to-end capabilities that are making recruitment faster, more precise, and more predictable.
Suzanne Caruso
President, Citeline Strategic Intelligence, Clinical & Regulatory
View profile
President, Citeline Strategic Intelligence, Clinical & Regulatory
Norstella
I’ve spent more than 15 years helping pharmaceutical companies plan and operationalize clinical trials, with leadership roles across Novartis, GSK, WCG, Veeva, and now Norstella. Having worked across clinical operations, data and strategic intelligence, I’ve seen firsthand where AI can remove friction from development and where human expertise remains essential.
What makes Norstella's AI different?
It starts with decades of proprietary clinical, pipeline and real-world data already organised around the way drug development works. This provides industry-specific context rather than generic information. Transparent sourcing and expert oversight make it possible for users to understand the evidence behind an AI-generated insight.
What can pharma teams do now that was not possible two years ago?
AI agents can handle many of the manual steps between posing a question and arriving at a usable answer. Fragmented information can be turned into a sourced, evidence-based output in minutes rather than days. AI combined with real-world data also allows teams to test study assumptions, identify patient populations and refine recruitment strategies at much greater speed and scale.
How can AI accelerate the journey from pipeline to patient?
Drug development involves numerous handoffs across systems, teams and decisions. AI can connect those workflows, automate routine analysis and surface relevant information at the right moment, leaving specialists to concentrate on the decisions requiring their expertise.
